Cost of Antivirals for HIV/AIDS Set to Increase
News Apr 06, 2012
Antiviral drugs for HIV/AIDS patients will become more expensive as doctors embrace new, highly-priced combination treatments, according to a new report by pharmaceutical industry experts GBI Research.
The new report shows that, in 2002, the annual treatment for HIV/AIDS cost an average of $9,971. This grew substantially at a compound average growth rate (CAGR) of 3.2% to $12,829 in 2010.
Correspondingly, revenue from the global HIV/AIDS therapeutics market grew at a CAGR of 10.9% during 2002-2010.
The annual cost of treatment for HIV/AIDS has increased steadily over the past decade, due to the launch of new combination therapies.
One example is the new, multi-class combination drug Atripla, a form of Highly Active Anti-Retroviral Therapy (HAART).
Sales of Atripla have soared over the last three years, demonstrating a CAGR of 136%. These expensive treatments have proven their worth through impressive efficacy, particularly in patients who have developed a resistance to other HIV/AIDS drugs.
This year will see the patent expiries of key drugs such as Sustiva and Combivir, while other medications such as Epivir, Epzicom, Trizivir, Ziagen, Invirase and Lexiva went off-patent in 2009 and 2010.
However, it is thought that the impact of new generics will be partially offset by increasing use of new and more expensive drug treatments.
The HIV/AIDS therapeutics market is expanding, due to decreased mortality and increasing treatment-seeking rates, which has encouraged further pharmaceutical innovation.
Gilead filed a New Drug Application (NDA) for Quad, a combination of Gilead’s pipeline candidate Elvitegravir, Cobicistat and its currently marketed HIV drug Truvada.
Late-stage pipeline drugs Edurant and Vicriviroc are also expected to enter the market during the forecast period, and will act as future drivers for growth.
The Discovery of Typhoid Toxin's Sweet Tooth Could Lead to New TreatmentsNews
"Our study shows that the typhoid toxin targets both the immune system and central nervous system... This represents a new paradigm in the infectious agents' incursion of the host." The new study shows how the toxin exclusively damages selected cells at the organism level, specifically seeking cells that express particular sugars because of their binding abilities.READ MORE
Single-Dose Vaccine Could Provide Faster Protection in Cholera EpidemicsNews
Each year there are more than three million cases of cholera worldwide, a disease transmitted through contaminated food and water that hits developing countries particularly hard. While the standard regimen for protecting against cholera with existing non-living oral cholera vaccines includes administering two doses over a two-week period, research now shows that giving a stronger single-dose of a live oral vaccine could be an effective tool in controlling outbreaks more quickly.READ MORE
Severity of Autoimmune Disease Influenced by Time of DayNews
Insights into how the body clock and time of day influence immune responses are revealed today. Understanding the effect of the interplay between 24-hour day-night cycles and the immune system may help inform drug-targeting strategies to alleviate autoimmune disease.